UK drafts plans to pay up to 25% more for meds to appease drugmakersnews2025-10-08T17:10:21+00:00October 8th, 2025|Endpoints News|
Lawyers scramble on how to advise clients on Trump’s 100% pharma tariff threat news2025-10-08T16:13:10+00:00October 8th, 2025|Endpoints News|
Eccogene files for Hong Kong IPO to back development of GLP-1 pipelinenews2025-10-08T14:50:39+00:00October 8th, 2025|Endpoints News|
Shanghai biotech claims Phase 2 win in endometriosis; Karyopharm’s $100Mnews2025-10-08T14:40:41+00:00October 8th, 2025|Endpoints News|
In the Lab: How Amgen sees AI changing pharma R&Dnews2025-10-08T14:00:50+00:00October 8th, 2025|Endpoints News|
Arthrosi raises $153M in Series E to complete two Phase 3 gout trialsnews2025-10-08T13:28:02+00:00October 8th, 2025|Endpoints News|
Endpoints Signal biotech sentiment survey: 4Q 2025news2025-10-08T12:55:36+00:00October 8th, 2025|Endpoints News|
In $2B biobucks pact, Zenas snags MS drug that Biogen returned to InnoCarenews2025-10-08T11:24:07+00:00October 8th, 2025|Endpoints News|
Dimerix says observational analysis could back speedier path to market for rare kidney disease drugnews2025-10-08T11:09:39+00:00October 8th, 2025|Endpoints News|
Sanofi and radioligand partner Orano Med report mid-stage win in rare tumornews2025-10-08T10:36:44+00:00October 8th, 2025|Endpoints News|
